The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of doxorubicin-loaded anti-EGFR immunoliposomes in patients with advanced solid tumors.
C. Mamot
Stock Ownership - LipoTarg GmbH
R. Ritschard
No relevant relationships to disclose
B. Vogel
No relevant relationships to disclose
T. Dieterle
No relevant relationships to disclose
L. Bubendorf
No relevant relationships to disclose
C. Hilker
No relevant relationships to disclose
S. Deuster
No relevant relationships to disclose
R. Herrmann
Employment or Leadership Position - LipoTarg GmbH (U)
Stock Ownership - LipoTarg GmbH
C. Rochlitz
Stock Ownership - LipoTarg GmbH